Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 3/20 | 0.43 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.42 |
| ▸ | BCHE | P06276 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 4/20 | 0.37 |
| ▸ | FLT1 | P17948 | 1/20 | 0.37 |
| ▸ | FLT4 | P35916 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 4/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | ITK | Q08881 | 1/20 | 0.35 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16295563 | 0.90 | ATM (0.47) | ATMENPP1BCHECNR2KDR | |
| SCHEMBL16295911 | 0.90 | ATM (0.47) | ATMENPP1BCHECNR2KDR | |
| SCHEMBL16295856 | 0.87 | ATM (0.42) | ATMENPP1BCHECNR2KDR | |
| SCHEMBL16294230 | 0.81 | ENPP1 (0.54) | ENPP1KDRFLT1FLT4EGFR | |
| SCHEMBL16294645 | 0.79 | ENPP1 (0.50) | ENPP1KDRFLT1EGFR | |
| SCHEMBL17967514 | 0.75 | ENPP1 (0.59) | ENPP1KDRFLT1EGFR | |
| SCHEMBL16295087 | 0.72 | ENPP1 (0.44) | ENPP1KDREGFR | |
| SCHEMBL27843809 | 0.71 | HDAC3 (0.45) | ENPP1KDRFLT1FLT4EGFR | |
| SCHEMBL19874812 | 0.70 | ENPP1 (0.41) | ENPP1KDR | |
| SCHEMBL13883179 | 0.69 | BCHE (0.47) | BCHECNR2EGFRIDO1ITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9549988-B2 | Pharmaceutical compounds targeted by MIF affinity-tethered moieties | RJS Biologics (US) | 2017-01-24 | — | — | US | disclosed |
| US-20150352217-A1 | Pharmaceutical Compounds Targeted by MIF Affinity-Tethered Moieties | RJS BIOLOGICS LLC | 2015-12-10 | — | — | US | disclosed |
| WO-2014200872-A9 | PHARMACEUTICAL COMPOUNDS TARGETED BY MIF AFFINITY-TETHERED MOIETIES | RJS BIOLOGICS LLC (US) | 2015-02-05 | — | — | WO | disclosed |
| WO-2014200872-A1 | PHARMACEUTICAL COMPOUNDS TARGETED BY MIF AFFINITY-TETHERED MOIETIES | RJS BIOLOGICS LLC (US) | 2014-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150352217-A1 | Pharmaceutical Compounds Targeted by MIF Affinity-Tethered Moieties | MIF, HMGB2, HMGB1 | ATM 3008/4885ENPP1 3752/4885BCHE 3858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.